Header Logo

Connection

DONALD BERRY to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications DONALD BERRY has written about Breast Neoplasms.
DONALD BERRY
Connection Strength
4.547
Breast Neoplasms
  1. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1355-1362.
    View in: PubMed
    Score: 0.137
  2. Concern Regarding Age Distribution of Breast Cancer. JAMA Surg. 2018 11 01; 153(11):1060-1061.
    View in: PubMed
    Score: 0.120
  3. A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality. Med Decis Making. 2018 04; 38(1_suppl):78S-88S.
    View in: PubMed
    Score: 0.110
  4. Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question-Reply. JAMA Oncol. 2017 03 01; 3(3):416-417.
    View in: PubMed
    Score: 0.107
  5. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 10 20; 375(16):1592-3.
    View in: PubMed
    Score: 0.105
  6. Right-Sizing Adjuvant and Neoadjuvant Clinical Trials in Breast Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):3-5.
    View in: PubMed
    Score: 0.098
  7. Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval. JAMA Oncol. 2015 Oct; 1(7):875-6.
    View in: PubMed
    Score: 0.097
  8. CYP2D6 genotype and adjuvant tamoxifen. Clin Pharmacol Ther. 2014 Aug; 96(2):138-40.
    View in: PubMed
    Score: 0.090
  9. Failure of researchers, reviewers, editors, and the media to understand flaws in cancer screening studies: application to an article in Cancer. Cancer. 2014 Sep 15; 120(18):2784-91.
    View in: PubMed
    Score: 0.089
  10. Response. J Natl Cancer Inst. 2014 Apr 03; 106(5).
    View in: PubMed
    Score: 0.088
  11. Response. J Natl Cancer Inst. 2014 Feb; 106(2):djt380.
    View in: PubMed
    Score: 0.086
  12. CYP2D6 genotyping and the use of tamoxifen in breast cancer. J Natl Cancer Inst. 2013 Sep 04; 105(17):1267-9.
    View in: PubMed
    Score: 0.084
  13. Breast cancer screening: controversy of impact. Breast. 2013 Aug; 22 Suppl 2:S73-6.
    View in: PubMed
    Score: 0.084
  14. Computer-assisted detection and screening mammography: where's the beef? J Natl Cancer Inst. 2011 Aug 03; 103(15):1139-41.
    View in: PubMed
    Score: 0.073
  15. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol. 2011 Aug 20; 29(24):3224-31.
    View in: PubMed
    Score: 0.073
  16. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol. 2011 Aug 20; 29(24):3214-23.
    View in: PubMed
    Score: 0.073
  17. Adjuvant chemotherapy for breast cancer in older women. Womens Health (Lond). 2009 Sep; 5(5):453-7.
    View in: PubMed
    Score: 0.064
  18. Flawed inferences about screening mammography's benefit based on observational data. J Clin Oncol. 2009 Feb 01; 27(4):639-40; author reply 641-2.
    View in: PubMed
    Score: 0.061
  19. The screening mammography paradox: better when found, perhaps better not to find. Br J Cancer. 2008 Jun 03; 98(11):1729-30.
    View in: PubMed
    Score: 0.058
  20. Building a predictive breast cancer risk model. AMIA Annu Symp Proc. 2007 Oct 11; 995.
    View in: PubMed
    Score: 0.056
  21. Breast cancer trends: a marriage between clinical trial evidence and epidemiology. J Natl Cancer Inst. 2007 Aug 01; 99(15):1139-41.
    View in: PubMed
    Score: 0.055
  22. Commentary: the hazards of survival comparisons. Oncologist. 2007 May; 12(5):510-1.
    View in: PubMed
    Score: 0.054
  23. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007 Apr 19; 356(16):1670-4.
    View in: PubMed
    Score: 0.054
  24. Biomarker studies and other difficult inferential problems: statistical caveats. Semin Oncol. 2007 Apr; 34(2 Suppl 3):S17-22.
    View in: PubMed
    Score: 0.054
  25. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12; 295(14):1658-67.
    View in: PubMed
    Score: 0.050
  26. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr. 2006; (36):30-6.
    View in: PubMed
    Score: 0.049
  27. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005 Oct 27; 353(17):1784-92.
    View in: PubMed
    Score: 0.049
  28. Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methods. Genet Epidemiol. 2005 Sep; 29(2):141-54.
    View in: PubMed
    Score: 0.048
  29. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005 Aug 17; 97(16):1195-203.
    View in: PubMed
    Score: 0.048
  30. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
    View in: PubMed
    Score: 0.043
  31. Commentary: screening mammography: a decision analysis. Int J Epidemiol. 2004 Feb; 33(1):68; discussion 69-73.
    View in: PubMed
    Score: 0.043
  32. Analysis of Breast Cancer Mortality in the US-1975 to 2019. JAMA. 2024 01 16; 331(3):233-241.
    View in: PubMed
    Score: 0.043
  33. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002 Jun 01; 20(11):2701-12.
    View in: PubMed
    Score: 0.039
  34. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 06 13; 40(6):609-623.e6.
    View in: PubMed
    Score: 0.039
  35. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Ann Oncol. 2022 08; 33(8):814-823.
    View in: PubMed
    Score: 0.038
  36. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 11 05; 12(1):6428.
    View in: PubMed
    Score: 0.037
  37. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 01; 7(11):1654-1663.
    View in: PubMed
    Score: 0.037
  38. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 2021 11; 301(2):295-308.
    View in: PubMed
    Score: 0.037
  39. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 07 12; 39(7):989-998.e5.
    View in: PubMed
    Score: 0.036
  40. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol. 2020 12 10; 38(35):4184-4193.
    View in: PubMed
    Score: 0.035
  41. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol. 2000 Oct 15; 18(20):3471-9.
    View in: PubMed
    Score: 0.034
  42. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 05 01; 6(5):676-684.
    View in: PubMed
    Score: 0.033
  43. Re: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1425.
    View in: PubMed
    Score: 0.032
  44. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.
    View in: PubMed
    Score: 0.032
  45. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 04 01; 38(10):1059-1069.
    View in: PubMed
    Score: 0.031
  46. Re: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1999 Feb 03; 91(3):286-7.
    View in: PubMed
    Score: 0.031
  47. Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1360-1369.
    View in: PubMed
    Score: 0.030
  48. Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1370-1379.
    View in: PubMed
    Score: 0.030
  49. Benefits and risks of screening mammography for women in their forties: a statistical appraisal. J Natl Cancer Inst. 1998 Oct 07; 90(19):1431-9.
    View in: PubMed
    Score: 0.030
  50. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res. 2018 11 01; 24(21):5292-5304.
    View in: PubMed
    Score: 0.030
  51. Contributions of Screening and Treatment to Mortality From Breast Cancer-Reply. JAMA. 2018 06 12; 319(22):2336.
    View in: PubMed
    Score: 0.029
  52. Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models. Med Decis Making. 2018 04; 38(1_suppl):3S-8S.
    View in: PubMed
    Score: 0.029
  53. Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nat Commun. 2018 03 23; 9(1):1219.
    View in: PubMed
    Score: 0.029
  54. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA. 2018 01 09; 319(2):154-164.
    View in: PubMed
    Score: 0.028
  55. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997 Feb 05; 89(3):227-38.
    View in: PubMed
    Score: 0.027
  56. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). J Am Coll Surg. 2017 Apr; 224(4):688-694.
    View in: PubMed
    Score: 0.027
  57. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat. 2017 01; 161(2):363-373.
    View in: PubMed
    Score: 0.026
  58. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016 11; 160(2):297-304.
    View in: PubMed
    Score: 0.026
  59. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22.
    View in: PubMed
    Score: 0.026
  60. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncol. 2016 Jun 01; 2(6):751-60.
    View in: PubMed
    Score: 0.025
  61. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Ann Intern Med. 2016 Feb 16; 164(4):215-25.
    View in: PubMed
    Score: 0.025
  62. Neoadjuvant as Future for Drug Development in Breast Cancer--Response. Clin Cancer Res. 2016 Jan 01; 22(1):269.
    View in: PubMed
    Score: 0.025
  63. Re: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005 Dec 21; 97(24):1853-4; author reply 1854.
    View in: PubMed
    Score: 0.025
  64. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 Dec 17; 366(9503):2087-106.
    View in: PubMed
    Score: 0.025
  65. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 2016 Feb 20; 34(6):542-9.
    View in: PubMed
    Score: 0.024
  66. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). J Natl Cancer Inst. 2015 Sep; 107(9).
    View in: PubMed
    Score: 0.024
  67. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5.
    View in: PubMed
    Score: 0.023
  68. Reply to V. Amoroso et al. J Clin Oncol. 2015 Jan 20; 33(3):291.
    View in: PubMed
    Score: 0.023
  69. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014 Nov; 106(11).
    View in: PubMed
    Score: 0.023
  70. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 01; 32(22):2311-7.
    View in: PubMed
    Score: 0.022
  71. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst. 2014 Jun; 106(6):dju092.
    View in: PubMed
    Score: 0.022
  72. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev. 2014; 36:114-36.
    View in: PubMed
    Score: 0.022
  73. Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al. J Clin Oncol. 2013 Dec 20; 31(36):4571-3.
    View in: PubMed
    Score: 0.021
  74. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013; 8(10):e79114.
    View in: PubMed
    Score: 0.021
  75. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013 Jul 01; 31(19):2382-7.
    View in: PubMed
    Score: 0.021
  76. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):457-66.
    View in: PubMed
    Score: 0.020
  77. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9.
    View in: PubMed
    Score: 0.020
  78. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(1):35-43.
    View in: PubMed
    Score: 0.020
  79. Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012 Nov 20; 30(33):4071-6.
    View in: PubMed
    Score: 0.019
  80. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9.
    View in: PubMed
    Score: 0.019
  81. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62.
    View in: PubMed
    Score: 0.019
  82. Modeling the impact of population screening on breast cancer mortality in the United States. Breast. 2011 Oct; 20 Suppl 3:S75-81.
    View in: PubMed
    Score: 0.018
  83. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat. 2012 Apr; 132(3):871-9.
    View in: PubMed
    Score: 0.018
  84. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 01; 17(15):5170-8.
    View in: PubMed
    Score: 0.018
  85. Breast cancer awareness month. Still awaiting screening facts. BMJ. 2010 Nov 02; 341:c6152.
    View in: PubMed
    Score: 0.017
  86. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol. 2010 May 10; 28(14):2418-22.
    View in: PubMed
    Score: 0.017
  87. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010 Feb 16; 102(4):651-7.
    View in: PubMed
    Score: 0.016
  88. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009 Nov 17; 151(10):738-47.
    View in: PubMed
    Score: 0.016
  89. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 01; 27(34):5700-6.
    View in: PubMed
    Score: 0.016
  90. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 6:S1-S21; quiz S22-3.
    View in: PubMed
    Score: 0.016
  91. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol. 2009 Jul 20; 27(21):3430-6.
    View in: PubMed
    Score: 0.016
  92. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65.
    View in: PubMed
    Score: 0.016
  93. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009 Jul; 86(1):97-100.
    View in: PubMed
    Score: 0.016
  94. Re: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1999 Apr 21; 91(8):728-9.
    View in: PubMed
    Score: 0.016
  95. Re: Benefits and risks of screening mammography for women in their forties: a statistical appraisal. J Natl Cancer Inst. 1999 Feb 17; 91(4):382-4.
    View in: PubMed
    Score: 0.015
  96. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol. 2008 Jul 10; 26(20):3338-45.
    View in: PubMed
    Score: 0.015
  97. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. J Clin Oncol. 2008 Jun 01; 26(16):2659-65.
    View in: PubMed
    Score: 0.015
  98. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1096-103.
    View in: PubMed
    Score: 0.015
  99. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol. 2008 May 10; 26(14):2364-72.
    View in: PubMed
    Score: 0.014
  100. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 01; 26(10):1642-9.
    View in: PubMed
    Score: 0.014
  101. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Res Treat. 2009 Feb; 113(3):479-90.
    View in: PubMed
    Score: 0.014
  102. Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol. 2008 Feb 10; 26(5):806-13.
    View in: PubMed
    Score: 0.014
  103. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30.
    View in: PubMed
    Score: 0.014
  104. Limited family structure and breast cancer risk. JAMA. 2007 Nov 07; 298(17):2007; author reply 2007-8.
    View in: PubMed
    Score: 0.014
  105. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11; 357(15):1496-506.
    View in: PubMed
    Score: 0.014
  106. Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med. 2007 Oct 02; 147(7):441-50.
    View in: PubMed
    Score: 0.014
  107. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007 Aug 20; 25(24):3699-704.
    View in: PubMed
    Score: 0.014
  108. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer. 2006 Oct 01; 107(7):1459-66.
    View in: PubMed
    Score: 0.013
  109. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol. 2006 Oct; 26(19):7269-82.
    View in: PubMed
    Score: 0.013
  110. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat. 2006 Dec; 100(3):301-8.
    View in: PubMed
    Score: 0.013
  111. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006 Feb 20; 24(6):863-71.
    View in: PubMed
    Score: 0.012
  112. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006; 8(6):R66.
    View in: PubMed
    Score: 0.012
  113. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8331-9.
    View in: PubMed
    Score: 0.012
  114. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 2005 Jul 01; 23(19):4287-97.
    View in: PubMed
    Score: 0.012
  115. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005 Mar 02; 293(9):1073-81.
    View in: PubMed
    Score: 0.012
  116. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85.
    View in: PubMed
    Score: 0.012
  117. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004 Sep 02; 351(10):971-7.
    View in: PubMed
    Score: 0.011
  118. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1337-42.
    View in: PubMed
    Score: 0.011
  119. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004 Jun 01; 22(11):2061-8.
    View in: PubMed
    Score: 0.011
  120. Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). Invest New Drugs. 2004 Jan; 22(1):83-9.
    View in: PubMed
    Score: 0.011
  121. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003 Aug; 83(4):803-19.
    View in: PubMed
    Score: 0.010
  122. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. J Clin Oncol. 2003 May 01; 21(9):1819-24.
    View in: PubMed
    Score: 0.010
  123. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol. 2003 May 01; 21(9):1825-35.
    View in: PubMed
    Score: 0.010
  124. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83.
    View in: PubMed
    Score: 0.010
  125. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9.
    View in: PubMed
    Score: 0.010
  126. Nonovarian pelvic cancers in BRCA1/2 mutation carriers and the BRCAPRO statistical model. J Clin Oncol. 2002 Sep 15; 20(18):3936; author reply 3936-7.
    View in: PubMed
    Score: 0.010
  127. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9.
    View in: PubMed
    Score: 0.010
  128. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res. 2002 Mar; 8(3):698-705.
    View in: PubMed
    Score: 0.009
  129. Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test. 2002; 6(2):93-105.
    View in: PubMed
    Score: 0.009
  130. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res. 2001 Sep; 7(9):2703-11.
    View in: PubMed
    Score: 0.009
  131. Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer. Bone Marrow Transplant. 2001 Jun; 27(12):1245-53.
    View in: PubMed
    Score: 0.009
  132. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol. 2001 Mar 15; 19(6):1698-706.
    View in: PubMed
    Score: 0.009
  133. Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst. 2000 Mar 15; 92(6):486-92.
    View in: PubMed
    Score: 0.008
  134. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000 Feb; 18(3):600-8.
    View in: PubMed
    Score: 0.008
  135. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol. 1999 Oct; 17(10):3064-74.
    View in: PubMed
    Score: 0.008
  136. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406.
    View in: PubMed
    Score: 0.008
  137. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol. 1999 May; 17(5):1465-73.
    View in: PubMed
    Score: 0.008
  138. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol. 1999 Mar; 17(3):1040-6.
    View in: PubMed
    Score: 0.008
  139. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. J Clin Oncol. 1999 Jan; 17(1):64-73.
    View in: PubMed
    Score: 0.008
  140. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst. 1998 Dec 02; 90(23):1824-9.
    View in: PubMed
    Score: 0.008
  141. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making. 1998 Oct-Dec; 18(4):365-75.
    View in: PubMed
    Score: 0.007
  142. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998 Sep 16; 90(18):1346-60.
    View in: PubMed
    Score: 0.007
  143. Overestimation of hereditary breast cancer risk. Ann Surg. 1998 Sep; 228(3):375-84.
    View in: PubMed
    Score: 0.007
  144. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998 Aug 19; 90(16):1205-11.
    View in: PubMed
    Score: 0.007
  145. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol. 1998 Mar; 16(3):1008-12.
    View in: PubMed
    Score: 0.007
  146. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998 Jan; 62(1):145-58.
    View in: PubMed
    Score: 0.007
  147. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer. 1998; 77(1):51-6.
    View in: PubMed
    Score: 0.007
  148. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver. Bone Marrow Transplant. 1998 Jan; 21(2):117-22.
    View in: PubMed
    Score: 0.007
  149. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol. 1998; 42(6):497-503.
    View in: PubMed
    Score: 0.007
  150. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant. 1997 Jun; 3(2):91-7.
    View in: PubMed
    Score: 0.007
  151. Relation of glutathione S-transferase alpha and mu isoforms to response to therapy in human breast cancer. Clin Cancer Res. 1997 May; 3(5):661-7.
    View in: PubMed
    Score: 0.007
  152. Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J Sci Am. 1997 Mar-Apr; 3(2):107-12.
    View in: PubMed
    Score: 0.007
  153. Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869. Cytometry. 1995 Dec 15; 22(4):297-306.
    View in: PubMed
    Score: 0.006
  154. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res. 1995 Jul; 1(7):699-704.
    View in: PubMed
    Score: 0.006
  155. A Bayesian group sequential design for a multiple arm randomized clinical trial. Stat Med. 1995 Feb 28; 14(4):381-94.
    View in: PubMed
    Score: 0.006
  156. High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB). Breast Cancer Res Treat. 1995; 36(1):35-40.
    View in: PubMed
    Score: 0.006
  157. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994 May 05; 330(18):1260-6.
    View in: PubMed
    Score: 0.006
  158. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg. 1994 Apr; 219(4):332-41.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.